An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
ApoPharma Identifier:
First received: January 9, 2013
Last updated: April 24, 2014
Last verified: April 2014

Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired hepatic function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg Ferriprox®.

Condition Intervention Phase
Hepatic Impairment
Drug: Ferriprox®
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: An Open-Label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox® in Subjects With Impaired Hepatic Function and Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by ApoPharma:

Primary Outcome Measures:
  • From serum and urine deferiprone concentration-time profiles: Cmax, Tmax, AUC0-t,AUC0-∞ ,T½ , CL/F,,CLr, Vd/F, Ae, Fe. From serum and urine deferiprone 3-O-glucuronide concentration-time profiles: Cmax, Tmax, AUC0-t, AUC0-∞, T½, CLr, Ae. [ Time Frame: Prior to dosing and at 0.25, 0.5, 0.75, 1, 1.333, 1.667, 2, 2.5, 3, 4, 6, 9, 12, 16 and 24 hours post-dose ] [ Designated as safety issue: No ]
    Pharmacokinetic parameters will be assessed over a 24 hour interval using blood and urine samples for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal, mild and moderate hepatic impairment.

Secondary Outcome Measures:
  • Safety and tolerability of Ferriprox® in subjects with hepatic impairment. [ Time Frame: Prior to dosing until 48 hours post-dose. ] [ Designated as safety issue: Yes ]
    Safety and tolerability will be assessed based on changes in: physical examinations, vital signs, 12-lead ECG, clinical laboratory tests, use of concomitant medication and frequency of adverse events (AEs) following a single dose of Ferriprox.

Enrollment: 21
Study Start Date: January 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Normal Hepatic Function (healthy volunteers)
Healthy volunteers with normal hepatic function will receive a single 33mg/kg dose of Ferriprox®.
Drug: Ferriprox®
Other Names:
  • DFP
  • Deferiprone
  • L1
Experimental: Mild Hepatic Failure
Mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points will receive a single 33mg/kg dose of Ferriprox®.
Drug: Ferriprox®
Other Names:
  • DFP
  • Deferiprone
  • L1
Experimental: Moderate Hepatic Failure
Moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points will receive a single 33 mg/kg dose of Ferriprox®.
Drug: Ferriprox®
Other Names:
  • DFP
  • Deferiprone
  • L1

Detailed Description:

Post-marketing study to evaluate the effect of impaired hepatic function on the pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite and on the safety of Ferriprox® in subjects with mild and moderate hepatic impairment as compared to healthy volunteers.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Main Inclusion Criteria:

All subjects:

  1. Adult males or females, 18 - 75 years of age (inclusive);
  2. Body weight ≥ 50 kg;
  3. Body mass index (BMI) between 19 and 32 kg/mE2 (inclusive);
  4. Absolute neutrophil count (ANC) of >1.5x10E9/L ;

Healthy volunteers:

  1. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical history, vital signs, physical examination);
  2. Matched to hepatically impaired subjects in the study by age (+/- 10 years), sex and weight (+/- 15% BMI).

Hepatically impaired subjects:

  1. Considered clinically stable in the opinion of the Investigator;
  2. Subjects with different degrees of impaired hepatic function as assessed by a Child-Pugh classification score: mild (Class A: 5-6 points) and moderate (Class B: 7-9 points) impaired hepatic function.

Main Exclusion Criteria:

  1. For subjects with hepatic impairment, fluctuating or rapidly deteriorating hepatic function as indicated by clinical and/or laboratory signs of hepatic impairment (e.g. advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding).
  2. Evidence of liver impairment in healthy volunteers: hepatitis B and C; or aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, clotting factors, serum protein that is considered clinically significant by the Investigator;
  3. History or presence of significant clinically unstable respiratory, cardiovascular, pulmonary, hepatic (except for subjects assigned to one of the hepatically impaired groups), renal, hematologic, gastrointestinal, endocrine (except for subjects with hepatic impairment with clinically stable and treated diabetes, hypertension and thyroid disorders), immunologic, dermatologic, neurologic, or psychiatric disease;
  4. Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the PK of the investigational medicinal product (e.g. resections of the small or large intestine, febrile conditions, chronic diarrhea, chronic vomiting, clinically unstable endocrine disease, severe infections, acute inflammations, etc.);
  5. Received a pharmacological agent in another clinical trial within 28 days prior to the first dose of the study;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01767103

United States, Florida
University of Miami
Miami, Florida, United States, 33136
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Study Chair: Fernando Tricta, MD ApoPharma
  More Information

No publications provided

Responsible Party: ApoPharma Identifier: NCT01767103     History of Changes
Other Study ID Numbers: LA40-0412
Study First Received: January 9, 2013
Last Updated: April 24, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by ApoPharma:
Hepatic Impairment
Liver Impairment
Liver Disease

Additional relevant MeSH terms:
Liver Diseases
Hepatic Insufficiency
Digestive System Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on August 28, 2014